Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction - Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction - Biogen is buying up an immune drug developer for $1.8 billion - Ozempic hits booze sales, Moderna likes AI, and Biogen's blockbuster drug: Pharma news roundup - Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up - Stocks making the biggest moves midday: JetBlue Airways, Shopify, Biogen and more - Biogen dumps dubious Alzheimer's drug after profit-killing FDA scandal - Biogen to stop selling controversial Alzheimer's drug Aduhelm - Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments - Biogen Quits Controversial Alzheimer's Drug Aduhelm